A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Wassim Abida, Yu Chen, Deaglan Joseph McHugh, Michael J. Morris, Frank Wu, Peng Peng, Katie Hennessy, Hui Wang, Jean Fan, Samir Zaidi
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407700360